Literature DB >> 29983806

A Saudi Infant with Vici Syndrome: Case Report and Literature Review.

Alhussain Alzahrani1, Abdulrahman Abdullah Alghamdi1, Rahaf Waggass1.   

Abstract

INTRODUCTION: Vici syndrome, a rare autosomal recessive disorder, was first described in 1988 by Vici et al. Only 78 cases have been reported to date. The syndrome is characterised by agenesis of the corpus callosum, hypopigmentation, cardiomyopathy, progressive failure to thrive, dysmorphic features, immunodeficiency and cataracts. Mutations in the gene epg5 have been identified as the cause of Vici syndrome. CASE DESCRIPTION: The parents are a consanguineous Saudi couple with two other children diagnosed with Gaucher disease. The patient was born at term and in the first 5 months had many hospital admissions for a recurrent chest infection. Physical examination, investigations and imaging studies revealed that the patient had agenesis of the corpus callosum, cataracts, psychomotor delay, immunodeficiency and hypopigmentation. The initial echocardiogram was normal. At 7 months, genetic testing confirmed the diagnosis of Vici syndrome with a c.3693G>Ap (Gln1231Gln) mutation in the gene EPG5. The patient developed a chest infection and was admitted to the pediatric intensive care unit. An echocardiogram was repeated and showed significant left ventricular dilation with a Z-score of 3.1, moderate mitral and tricuspid regurgitation, and depressed ventricular function with a fractional shortening of 17% and ejection fraction 37%. The patient's condition deteriorated, and he died aged 8 months.
CONCLUSION: The symptoms of extensive system involvement in Vici syndrome have been present in the majority of reported cases and should prompt careful evaluation of this syndrome when such symptoms are present in an infant. In confirmed cases, close monitoring of the immune status and cardiac function, the two main causes of death among Vici syndrome patients, is vital to prevent rapid deterioration and improve life expectancy.

Entities:  

Keywords:  Cardiomyopathy; EPG5 gene; Vici syndrome

Year:  2018        PMID: 29983806      PMCID: PMC6026433          DOI: 10.3889/oamjms.2018.271

Source DB:  PubMed          Journal:  Open Access Maced J Med Sci        ISSN: 1857-9655


Introduction

Vici syndrome (VICIS) (OMIM 242840) is a rare autosomal recessive disease belonging to the group of congenital disorders of autophagy. The syndrome has a wide range of presentations involving various body systems [1] [2] and is caused by a mutation in epg5, the gene for ectopic P-granules protein 5 (EPG5) on chromosome 18 [2]. The EPG5 protein is responsible for regulating autophagy activity, a pivotal mechanism for the development and proper functioning of body organs. The first two cases were described by Vici and his colleagues in 1988 when they reported on two siblings with a set of clinical features comprising agenesis of the corpus callosum, cutaneous hypopigmentation, bilateral cataract, cleft lip and palate, and combined immunodeficiency [3]. Since that original description of the disorder, an increasing number of cases have been reported, with almost 78 confirmed cases published to date [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22]. The patients have presented, mostly in infancy, with characteristic features of VICIS together with other phenotypic features such as progressive failure to thrive, microcephaly, nystagmus, dysmorphic features, cardiomyopathy, hypotonia, and recurrent pulmonary infection, among others [4]. Features such as hearing loss, lung hypoplasia, and renal tubular necrosis have also been described in isolated cases [6] [7] [8]. In this report, which includes a review of all literature to date, we describe in detail a previously reported case [9] of an 8-month-old male infant diagnosed with VICIS.

Case Description

We report on a boy, the third child of healthy consanguineous first-cousin Saudi parents. His two brothers are confirmed cases of Gaucher disease. The boy is a product of spontaneous vaginal delivery at 36 weeks gestational age with birth weight 3.2 kg. At 10 days of age, he was admitted to the neonatal intensive care unit because of meconium aspiration and group B streptococcus sepsis. During the first month of life at home, the patient developed poor sucking and choking attacks with each feeding. At the age of 2 months, he was admitted to an outside hospital as a case of aspiration pneumonia and was treated accordingly. Diagnosis of gastroesophageal reflux disease was also made, and he underwent a fundoplication. During that admission, the patient was evaluated for the choking attacks and hypotonia. Chromosomal analysis revealed a normal karyotype (46XY). At 5 months of age he was admitted to our hospital, for the first time, as a case of pneumonia. On physical examination, he also had profound hypotonia and albinism. Abdominal ultrasound was unremarkable and ruled out any organomegaly for other metabolic syndromes. Visual evoked response (VER) was significant for bilateral P100 prolongation and abnormal NPN configuration. VICIS was suspected as a cause of his multisystem symptoms. Magnetic resonance imaging (MRI) of the brain showed complete agenesis of corpus callosum, hypoplastic pons, and volume loss of white matter (Figure 1). Echocardiographic evaluation showed normal function with only mild left ventricular hypertrophy and fractional shortening of 33.1%. Genetic testing identified a pathogenic variant of epg5 (c.3693G>A p. (Gln1231Gln) and confirmed the diagnosis of VICIS.
Figure 1

Brain MRI at age 6 months. Medline sagittal T1 weighted sequence (A), showing agenesis of corpus callosum and hypoplastic pons. Coronal T1 (B) and axial T2 (C) showing loss of white matter and dilated ventricular system

Brain MRI at age 6 months. Medline sagittal T1 weighted sequence (A), showing agenesis of corpus callosum and hypoplastic pons. Coronal T1 (B) and axial T2 (C) showing loss of white matter and dilated ventricular system Following this admission, the patient presented several times to our hospital with recurrent infections including bronchial pneumonia, urinary tract infection and gastroenteritis. At the age of 7 months he presented to the emergency department following a 3-week episode of bloody diarrhea with severe dehydration. On physical examination, the patient looked pale, cachectic, not oriented, with sunken eyes and anterior fontanelles. His arterial blood gases revealed hypokalemia with metabolic acidosis (K = 2 mmol/L, pH = 7.28, PCO2 = 37 torr, HCO3 = 16.8 mmol/L). His weight had dropped 2.1 kg from the admission a month previously. He was admitted to the pediatric intensive care unit for rehydration and monitoring. During the course of this admission, the immunologic workup revealed reduced absolute B and T cell counts; immunoglobulins A, M and G were within the normal range. A few days later, the patient suddenly became apneic and developed respiratory distress. Chest X-ray revealed cardiomegaly. Repeated echocardiography showed dilated cardiomyopathy. His echocardiogram findings were significant for left ventricular dilation with a Z-score of 3.1, moderate mitral and tricuspid regurgitation, and depressed ventricular function with fractional shortening of 17% and ejection fraction 37%. He deteriorated quickly and developed renal impairment, which worsened his electrolyte imbalance and metabolic acidosis. Eventually, the patient went into cardiopulmonary arrest and died.

Discussion

VICIS is a rare disease that affects multiple systems of the body. Since the condition was first described in 1988, a total of 78 cases —including our patient’s—have been reported (Table 1). The incidence of this disease is yet to be determined. VICIS was first linked to a recessive mutation in EPG5 in 2013 [1]. The EPG5 protein is responsible for regulating autophagy activity, which is a survivor-cell mechanism that selectively removes misfolded proteins and organelles and plays a paramount role in ensuring good development of body systems, especially the nervous system. In our patient, genetic testing showed a c.3693G>A p.(Gln1231Gln) mutation in epg5, confirming the diagnosis of VICIS.
Table 1

Summary of reported patients with Vici syndrome

Authors, yearSexAge (m)Clinical outcome
Vici et al., 1988 [3]M24Deceased
M36
Del Campo et al., 1999 [4]M24Deceased
F11Deceased
M36Alive
F16Deceased
Chiyonobu et al., 2002 [5]F19Deceased
M6Alive
Miyata et al., 2007 [6]F12Deceased
M11Alive
McClelland et al., 2010 [7]M3Deceased
Al-Owain et al., 2010 [8]M9Deceased
Rogers et al., 2011 [10]M96Deceased
F96Deceased
Said et al., 2012 [11]F15Deceased
Finocchi et al., 2012 [12]M24Alive
Özkale et al., 2012 [13]F6Deceased
Cullup et al., 2013 [1]F15Deceased
M3Alive
M48Alive
M36Alive
M9Alive
M36Alive
M24Alive
M24Alive
F120Alive
Ehmke et al., 2014 [14]M3.5Deceased
Filloux et al., 2014 [15]F17Alive
Tasdemir et al., 2015 [16]M9Deceased
M8
El-Kersh et al., 2015 [17]F72Deceased
Byrne et al., 2016 [2]NSNSNS
Huenerberg et al., 2016 [18]F11Deceased
F13
Maillard et al., 2017 [19]F24Alive
Hori et al., 2017 [20]F84Alive
F24Alive
F180Alive
F12Deceased
F48Alive
F24Alive
M168Deceased
M60Alive
M84Alive
Hedberg-Oldfors et al., 2017 [21]M8Deceased
Elsayed et al., 2018 [22]M7Deceased
This CaseM8Deceased

M = male; F = female; NS = not specified; m months.

Summary of reported patients with Vici syndrome M = male; F = female; NS = not specified; m months. Table 2 summarizes all the important features that have been associated with VICIS to date. The majority of reported cases were associated with recurrent infections (98.7%), agenesis of corpus callosum (97.4%), profound developmental delay (97.4%), skin involvement (96.2%), immunodeficiency (76.9%), cataract (62.8%) and cardiomyopathy (65.4%) with the hypertrophic type being most commonly reported. We suggest, therefore, that VICIS should be considered to head the list of differential diagnoses for an infant who presents with all or most of these features.
Table 2

Common clinical features of 78 cases of Vici syndrome

FeaturePositiveNegativeNot reportedn (%)
Recurrent infections77-177/78 (98.7)
Corpus callosum agenesis76-276/78 (97.4)
Profound developmental delay761176/78 (97.4)
Cutaneous manifestations753-75/78 (96.2)
Immune system involvement6016260/78 (76.9)
Cardiomyopathy5118951/78 (65.4)
Cataract4925449/78 (62.8)
Microcephaly45151845/78 (57.7)
Hypotonia37-4137/78 (47.4)
Seizures26163626/78 (33.3)
Growth retardation24-5424/78 (30.8)
Common clinical features of 78 cases of Vici syndrome Our findings support those published in a review of 38 cases [2] of VICIS where agenesis of corpus callosum, profound developmental delay and immune problems were the most common shared features. Concurrently with the clinical assessment, there are multiple investigations to help shorten the list of differential diagnoses and assess the extent of organ involvement [23] [24]. Such tests include laboratory investigation, imaging, molecular and other tests. Laboratory investigations will be directed to assess immunodeficiency and the extent of involvement of other organs such as liver and kidneys. For imaging, a brain MRI is essential for detection of agenesis of corpus callosum and other less specific neuroradiologic abnormalities that have been reported, such as vermis and pons hypoplasia. Chest X-ray and echocardiography are also of benefit for assessing lung and cardiac involvement, respectively. Abdominal ultrasonography helps to confirm laboratory findings, whether abdominal organs are affected or not. Confirmation of diagnosis requires molecular genetic testing to identify the homogenous or compound heterogenous mutated epg5. Other useful tests for VICIS cases are ophthalmologic tests and electroencephalography (EEG), especially if seizures are present. Our patient underwent all these investigations apart from the EEG, as seizures were absent; this helped to confirm the diagnosis and identify the present complications, thus allowing us to tailor our interventions. VICIS is a progressive disease with poor prognosis. Survival analysis shows that VICIS patients have a median survival time of 24 months (95% confidence interval, 0–39 months) [2]. Thus, therapeutic interventions for VICIS are merely supportive and directed to relieve the symptoms that result from multi-organ involvement and to improve the survival time. The most common causes of death among all reported patients with VICIS are recurrent infections and cardiomyopathy. Cardiac functions, in particular, can deteriorate from baseline in a short time, as happened in our patient. Immunity status and cardiac function, therefore, need to be regularly monitored at short intervals for early detection of their VICIS-related manifestations, thus allowing timely intervention for a better outcome and prolonged survival. In conclusion, in VICIS, the symptoms of extensive system involvement (such as agenesis of corpus callosum, profound developmental delay, recurrent infections and immunodeficiency) that present in the majority of cases should prompt a careful evaluation for this syndrome. When the diagnosis is confirmed, close monitoring of the immune status and cardiac function is vital to prevent rapid deterioration and improve life expectancy, as these have been the two main causes of death among VICIS patients in all known cases to date.
  22 in total

Review 1.  Sibling cases of Vici syndrome: sleep abnormalities and complications of renal tubular acidosis.

Authors:  Rie Miyata; Masaharu Hayashi; Hiroyuki Sato; Yuji Sugawara; Takako Yui; Satoshi Araki; Takeshi Hasegawa; Shozaburo Doi; Jun Kohyama
Journal:  Am J Med Genet A       Date:  2007-01-15       Impact factor: 2.802

Review 2.  First description of a patient with Vici syndrome due to a mutation affecting the penultimate exon of EPG5 and review of the literature.

Authors:  Nadja Ehmke; Nima Parvaneh; Peter Krawitz; Mahmoud-Reza Ashrafi; Parviz Karimi; Mehrzad Mehdizadeh; Ulrike Krüger; Jochen Hecht; Stefan Mundlos; Peter N Robinson
Journal:  Am J Med Genet A       Date:  2014-10-20       Impact factor: 2.802

Review 3.  Muscle pathology in Vici syndrome-A case study with a novel mutation in EPG5 and a summary of the literature.

Authors:  Carola Hedberg-Oldfors; Niklas Darin; Anders Oldfors
Journal:  Neuromuscul Disord       Date:  2017-05-08       Impact factor: 4.296

4.  Severe Central Sleep Apnea in Vici Syndrome.

Authors:  Karim El-Kersh; Heinz Jungbluth; Paul Gringras; Egambaram Senthilvel
Journal:  Pediatrics       Date:  2015-10-19       Impact factor: 7.124

Review 5.  Vici syndrome in siblings born to consanguineous parents.

Authors:  Sener Tasdemir; Ibrahim Sahin; Atilla Cayır; Ihsan Yuce; Serdar Ceylaner; Abdulgani Tatar
Journal:  Am J Med Genet A       Date:  2015-09-23       Impact factor: 2.802

6.  Immunodeficiency in Vici syndrome: a heterogeneous phenotype.

Authors:  Andrea Finocchi; Giulia Angelino; Nicoletta Cantarutti; Maurizio Corbari; Elsa Bevivino; Simona Cascioli; Francesco Randisi; Enrico Bertini; Carlo Dionisi-Vici
Journal:  Am J Med Genet A       Date:  2011-09-30       Impact factor: 2.802

7.  Vici syndrome--a rapidly progressive neurodegenerative disorder with hypopigmentation, immunodeficiency and myopathic changes on muscle biopsy.

Authors:  Edith Said; Doriette Soler; Caroline Sewry
Journal:  Am J Med Genet A       Date:  2011-09-30       Impact factor: 2.802

Review 8.  Albinism and agenesis of the corpus callosum with profound developmental delay: Vici syndrome, evidence for autosomal recessive inheritance.

Authors:  M del Campo; B D Hall; A Aeby; M C Nassogne; A Verloes; C Roche; C Gonzalez; H Sanchez; A Garcia-Alix; F Cabanas; R M Escudero; R Hernandez; J Quero
Journal:  Am J Med Genet       Date:  1999-08-27

9.  Prenatal and postnatal presentations of corpus callosum agenesis with polymicrogyria caused by EGP5 mutation.

Authors:  Camille Maillard; Mara Cavallin; Kevin Piquand; Marion Philbert; Jean Philippe Bault; Anne Elodie Millischer; Despina Moshous; Marlène Rio; Cyril Gitiaux; Nathalie Boddaert; Cecile Masson; Sophie Thomas; Nadia Bahi-Buisson
Journal:  Am J Med Genet A       Date:  2017-02-07       Impact factor: 2.802

10.  Defects in autophagosome-lysosome fusion underlie Vici syndrome, a neurodevelopmental disorder with multisystem involvement.

Authors:  Ikumi Hori; Takanobu Otomo; Mitsuko Nakashima; Fuyuki Miya; Yutaka Negishi; Hideaki Shiraishi; Yutaka Nonoda; Shinichi Magara; Jun Tohyama; Nobuhiko Okamoto; Takeshi Kumagai; Konomi Shimoda; Yoshiya Yukitake; Daigo Kajikawa; Tomohiro Morio; Ayako Hattori; Motoo Nakagawa; Naoki Ando; Ichizo Nishino; Mitsuhiro Kato; Tatsuhiko Tsunoda; Hirotomo Saitsu; Yonehiro Kanemura; Mami Yamasaki; Kenjiro Kosaki; Naomichi Matsumoto; Tamotsu Yoshimori; Shinji Saitoh
Journal:  Sci Rep       Date:  2017-06-14       Impact factor: 4.379

View more
  4 in total

1.  Human platelets display dysregulated sepsis-associated autophagy, induced by altered LC3 protein-protein interaction of the Vici-protein EPG5.

Authors:  Hansjörg Schwertz; Jesse W Rowley; Irina Portier; Elizabeth A Middleton; Neal D Tolley; Robert A Campbell; Alicia S Eustes; Karin Chen; Matthew T Rondina
Journal:  Autophagy       Date:  2021-11-18       Impact factor: 13.391

Review 2.  Cardiomyopathies in Children and Systemic Disorders When Is It Useful to Look beyond the Heart?

Authors:  Valentina Lodato; Giovanni Parlapiano; Federica Calì; Massimo Stefano Silvetti; Rachele Adorisio; Michela Armando; May El Hachem; Antonino Romanzo; Carlo Dionisi-Vici; Maria Cristina Digilio; Antonio Novelli; Fabrizio Drago; Massimiliano Raponi; Anwar Baban
Journal:  J Cardiovasc Dev Dis       Date:  2022-01-31

3.  Intestinal antiviral signaling is controlled by autophagy gene Epg5 independent of the microbiota.

Authors:  Sanghyun Lee; Gowri Kalugotla; Harshad Ingle; Rachel Rodgers; Chunyan Wu; Yating Wang; Yuhao Li; Xia Yang; Jin Zhang; Nicolette R Borella; Hongju Deng; Lindsay Droit; Ryan Hill; Stefan T Peterson; Chandni Desai; Dylan Lawrence; Qun Lu; Megan T Baldridge
Journal:  Autophagy       Date:  2021-09-14       Impact factor: 13.391

4.  Vici syndrome in Israel: Clinical and molecular insights.

Authors:  Odelia Chorin; Yoel Hirsch; Rachel Rock; Liat Salzer Sheelo; Yael Goldberg; Hanna Mandel; Tova Hershkovitz; Nicole Fleischer; Lior Greenbaum; Uriel Katz; Ortal Barel; Nasrin Hamed; Bruria Ben-Zeev; Shoshana Greenberger; Nadra Nasser Samra; Michal Stern Zimmer; Annick Raas-Rothschild; Ben Pode-Shakked
Journal:  Front Genet       Date:  2022-09-20       Impact factor: 4.772

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.